PACB · Nasdaq · ·
Next earnings: November 4, 2026
$1.84+7.3%Sep 29 close
Pacific Biosciences Of California, Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $39M | $39.8M | -1.91% |
| Profit | -$44.7M | -$41.9M | -6.70% |
| Profit per share | -$0.14 | -$0.14 | 0.00% |
| Free Cash Flow | -$37.1M | -$29.9M | -24.10% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Releases land after the close or before the open, so the move is the session that follows.
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies, which primarily consist of our HiFi long-read sequencing systems, address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Pacific Biosciences Of California, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Pacific Biosciences Of California, Inc. has no earnings call transcript available.